Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000897069-24-000253)

Filing Details

Accession Number:: 0000897069-24-000253
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-07 16:22:44
Reporting Period:: 2024-02-06

Accepted Time:: 2024-02-07 16:22:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1533743	Processa Pharmaceuticals Inc.	PCSA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1378166	David Young	C/O Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover MD 21076	Pres. Research & Development	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-02-06	20,000	$2.53	58,387	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	30,985	Indirect	By Young-Plaisance Revocable Trust
Common Stock	10,786	Indirect	By Family Entities
Common Stock	18,544	Indirect	By CorLyst, LLC

Footnotes

Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.